Hemophilia A cost-effectiveness of therapy: Difference between revisions
Fahd Yunus (talk | contribs) No edit summary |
Fahd Yunus (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hemophilia A}} | {{Hemophilia A}} | ||
{{CMG}} {{FNY}} | {{CMG}}{{AE}}{{FNY}} | ||
==Overview== | ==Overview== | ||
| Line 7: | Line 7: | ||
==Cost-effectiveness of therapy== | ==Cost-effectiveness of therapy== | ||
Long-term prophylaxis, particularly for patients with severe hemophilia, has been shown to be cost-effective as it decreases the otherwise high cost of managing recurrent joint bleeds and improves quality of life overall. <ref> Prophylaxis: Barriers and challenges – World Federation of Hemophilia. Available at http://www.wfh.org/en/abd/prophylaxis/prophylaxis-barriers-and-challenges. Accessed on Sept 20, 2016 </ref> Further research is required to address the issue of cost-effectiveness for therapy in hemophilia A. In particular, further research would be helpful to determine the optimal dosing schedule for prophylaxis, and the optimal target ranges of clotting factor levels. These studies are especially needed in countries with limited resources, where access to prophylaxis is limited. | Long-term prophylaxis, particularly for patients with severe hemophilia, has been shown to be cost-effective as it decreases the otherwise high cost of managing recurrent joint bleeds and improves quality of life overall.<ref> Prophylaxis: Barriers and challenges – World Federation of Hemophilia. Available at http://www.wfh.org/en/abd/prophylaxis/prophylaxis-barriers-and-challenges. Accessed on Sept 20, 2016 </ref> Further research is required to address the issue of cost-effectiveness for therapy in hemophilia A. In particular, further research would be helpful to determine the optimal dosing schedule for prophylaxis, and the optimal target ranges of clotting factor levels. These studies are especially needed in countries with limited resources, where access to prophylaxis is limited. | ||
==References== | ==References== | ||
Revision as of 06:01, 16 April 2017
|
Hemophilia A Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemophilia A cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Hemophilia A cost-effectiveness of therapy |
|
Risk calculators and risk factors for Hemophilia A cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Fahd Yunus, M.D. [2]
Overview
Though long-term prophylaxis has been shown to be beneficial in decreasing incidence of bleeding events in patients with Hemophilia A, the major barrier to its implementation is high cost.
Cost-effectiveness of therapy
Long-term prophylaxis, particularly for patients with severe hemophilia, has been shown to be cost-effective as it decreases the otherwise high cost of managing recurrent joint bleeds and improves quality of life overall.[1] Further research is required to address the issue of cost-effectiveness for therapy in hemophilia A. In particular, further research would be helpful to determine the optimal dosing schedule for prophylaxis, and the optimal target ranges of clotting factor levels. These studies are especially needed in countries with limited resources, where access to prophylaxis is limited.
References
- ↑ Prophylaxis: Barriers and challenges – World Federation of Hemophilia. Available at http://www.wfh.org/en/abd/prophylaxis/prophylaxis-barriers-and-challenges. Accessed on Sept 20, 2016